Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1997-6-26
|
| pubmed:abstractText |
Sixty-two patients with stage III non-small cell lung cancer (NSCLC) were treated with neoadjuvant chemotherapy consisting of cisplatin 120 mg/m2 day 1, mitomycin 8 mg/m2 day 1, and vindesine 3 mg/m2 days 1 and 14. Each cycle was repeated every 4 weeks for a total of 1 to 6 cycles (median, 3 cycles). Resection was attempted 4 to 5 weeks after the last course of chemotherapy. Intraoperative radiation therapy (IORT) (10-15 Gy) was delivered during surgery and postoperative external beam radiotherapy (EBRT) (46 Gy) was begun 4 weeks after surgery. Fifty-five patients (25 IIIA, 30 IIIB) were evaluable. Only partial responses occurred (64%), and 29 patients (53%) underwent resection. Complete resection rates were 85% (12/14) and 40% (6/15) in stage IIIA and IIIB, respectively (p = 0.01). In 3 of 29 patients (10%), no tumor was found in the resected specimen. There was one chemotherapy-related death and three postoperative-related deaths. The median survival time was 10 months, and the 5-year survival rate was 29 and 7% for stage IIIA and stage IIIB, respectively (p = 0.3). High complete resection rates and modest increase in 5-year survival have been observed in stage IIIA NSCLC. Although a number of stage IIIB patients can be made technically resectable, the low complete resectability rate reflects the lack of survival benefit in these patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Mitomycins,
http://linkedlifedata.com/resource/pubmed/chemical/Vindesine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0277-3732
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
276-81
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:9167753-Adult,
pubmed-meshheading:9167753-Aged,
pubmed-meshheading:9167753-Antibiotics, Antineoplastic,
pubmed-meshheading:9167753-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9167753-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9167753-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9167753-Chemotherapy, Adjuvant,
pubmed-meshheading:9167753-Cisplatin,
pubmed-meshheading:9167753-Female,
pubmed-meshheading:9167753-Humans,
pubmed-meshheading:9167753-Intraoperative Care,
pubmed-meshheading:9167753-Lung Neoplasms,
pubmed-meshheading:9167753-Male,
pubmed-meshheading:9167753-Middle Aged,
pubmed-meshheading:9167753-Mitomycins,
pubmed-meshheading:9167753-Neoplasm Staging,
pubmed-meshheading:9167753-Postoperative Care,
pubmed-meshheading:9167753-Radiotherapy, Adjuvant,
pubmed-meshheading:9167753-Survival Analysis,
pubmed-meshheading:9167753-Treatment Outcome,
pubmed-meshheading:9167753-Vindesine
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study.
|
| pubmed:affiliation |
Department of Radiation Oncology, Clinica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|